Keryx Biopharma (KERX) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.39), $0.19 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.37 million.
At September 30, 2016, the company had cash and cash equivalents of $132.2 million.
For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- PACCAR (PCAR) Reports In-Line Q3 EPS
- Freeport-McMoran (FCX) Tops Q3 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
